{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:57:07Z","timestamp":1774648627570,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biliary tract cancers (BTC) are rare and aggressive malignancies originating from intrahepatic and extrahepatic bile ducts and the gallbladder. Surgery is the only curative option, but due to late-stage diagnosis, is frequently not feasible, leaving chemotherapy as the primary treatment. Radiotherapy (RT) can be an effective alternative for patients with unresectable, non-metastatic BTC despite the generally poor prognosis and significant variability. To help manage patients with unresectable BTC who receive RT, we aimed to identify prognostic markers that could aid in predicting overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at the University of Pennsylvania, involving seventy-eight patients with unresectable BTC treated with definitive intent RT. Comprehensive demographic, clinical, and treatment-related data were extracted from the electronic medical records. Univariate and multivariate Cox regressions were employed to identify predictors of OS after RT. A biomarker model was developed for refined survival prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort primarily comprised patients with good performance status without significant hepatic dysfunction at presentation. The predominant treatment approach involved hypofractionated RT or concurrent 5FU-based chemoRT. Median OS after RT was 12.3 months, and 20 patients (15.6%) experienced local progression with a median time of 30.1 months. Univariate and multivariate analyses identified CA19-9 (above median) and higher albumin-bilirubin (ALBI) grades at presentation as significant predictors of poor OS. Median OS after RT was 24 months for patients with no risk factors and 6.3 months for those with both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study demonstrates generally poor but significantly heterogeneous OS in patients with unresectable BTC treated with RT. We have developed a biomarker model based on CA19-9 and ALBI grade at presentation that can distinguish sub-populations with markedly diverse prognoses. This model can aid the clinical management of this challenging disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-024-02481-y","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:35:30Z","timestamp":1722497730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Uri","family":"Amit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misra","family":"Shagun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Karasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryanne J.","family":"Lubas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Ben-Josef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2481_CR1","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1200\/EDBK_160831","volume":"35","author":"JA Bridgewater","year":"2016","unstructured":"Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educational book Am Soc Clin Oncol Annual Meeting. 2016;35:e194\u2013203.","journal-title":"Am Soc Clin Oncol Educational book Am Soc Clin Oncol Annual Meeting"},{"key":"2481_CR2","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","volume":"21","author":"SH Tella","year":"2020","unstructured":"Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21:e29\u201341.","journal-title":"Lancet Oncol"},{"key":"2481_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"2481_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (keynote-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2023;401:1853\u201365.","journal-title":"Lancet (London England)"},{"key":"2481_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"2481_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line folfox chemotherapy versus active symptom control for advanced biliary tract cancer (abc-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol"},{"key":"2481_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0360-3016(97)00299-X","volume":"39","author":"ML Foo","year":"1997","unstructured":"Foo ML, Gunderson LL, Bender CE, et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys. 1997;39:929\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2481_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00280-016-3143-2","volume":"78","author":"KJ Lee","year":"2016","unstructured":"Lee KJ, Yi SW, Cha J, et al. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemother Pharmacol. 2016;78:841\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2481_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/1471-2407-13-568","volume":"13","author":"L Moureau-Zabotto","year":"2013","unstructured":"Moureau-Zabotto L, Turrini O, Resbeut M, et al. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer. 2013;13:568.","journal-title":"BMC Cancer"},{"key":"2481_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0360-3016(02)02845-6","volume":"53","author":"CH Crane","year":"2002","unstructured":"Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53:969\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2481_CR11","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.21873\/anticanres.13445","volume":"39","author":"S Bisello","year":"2019","unstructured":"Bisello S, Buwenge M, Palloni A, et al. Radiotherapy or chemoradiation in unresectable biliary cancer: a retrospective study. Anticancer Res. 2019;39:3095\u2013100.","journal-title":"Anticancer Res"},{"key":"2481_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00066-004-1315-1","volume":"180","author":"TB Brunner","year":"2004","unstructured":"Brunner TB, Schwab D, Meyer T, et al. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]. 2004;180:751\u20137.","journal-title":"Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]"},{"key":"2481_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ijrobp.2006.05.061","volume":"66","author":"MA Ben-David","year":"2006","unstructured":"Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66:772\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2481_CR14","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1002\/cam4.1734","volume":"7","author":"D Elganainy","year":"2018","unstructured":"Elganainy D, Holliday EB, Taniguchi CM, et al. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018;7:4880\u201392.","journal-title":"Cancer Med"},{"key":"2481_CR15","first-page":"102","volume":"62","author":"SC Chen","year":"2015","unstructured":"Chen SC, Chen MH, Li CP, et al. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma. Hepatogastroenterology. 2015;62:102\u20137.","journal-title":"Hepatogastroenterology"},{"key":"2481_CR16","unstructured":"NCI. National cancer institute common terminology criteria for adverse events (CTCAE), Version 4.0. 2010. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 17 May 2010."},{"key":"2481_CR17","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/or.2013.2290","volume":"29","author":"R Dhanasekaran","year":"2013","unstructured":"Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29:1259\u201367.","journal-title":"Oncol Rep"},{"key":"2481_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","volume":"1","author":"MK Goel","year":"2010","unstructured":"Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1:274\u20138.","journal-title":"Int J Ayurveda Res"},{"key":"2481_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jamcollsurg.2015.04.009","volume":"221","author":"A Doussot","year":"2015","unstructured":"Doussot A, Groot-Koerkamp B, Wiggers JK, et al. Outcomes after resection of intrahepatic cholangiocarcinoma: external validation and comparison of prognostic models. J Am Coll Surg. 2015;221:452\u201361.","journal-title":"J Am Coll Surg"},{"key":"2481_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Reviews Disease Primers. 2021;7:65.","journal-title":"Nat Reviews Disease Primers"},{"key":"2481_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/hepr.12605","volume":"46","author":"S Mosadeghi","year":"2016","unstructured":"Mosadeghi S, Liu B, Bhuket T, et al. Sex-specific and race\/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: an updated analysis of the 2000\u20132011 surveillance, epidemiology and end results registry. Hepatol Research: Official J Japan Soc Hepatol. 2016;46:669\u201377.","journal-title":"Hepatol Research: Official J Japan Soc Hepatol"},{"key":"2481_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology (Baltimore MD). 2011;54:173\u201384.","journal-title":"Hepatology (Baltimore MD)"},{"key":"2481_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","volume":"16","author":"SKR Mukkamalla","year":"2018","unstructured":"Mukkamalla SKR, Naseri HM, Kim BM, et al. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Cancer Network: JNCCN. 2018;16:370\u20136.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"2481_CR24","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1111\/jgh.13339","volume":"31","author":"AW Chan","year":"2016","unstructured":"Chan AW, Chong CC, Mo FK, et al. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis b-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1766\u201372.","journal-title":"J Gastroenterol Hepatol"},{"key":"2481_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/bjs.10095","volume":"103","author":"YY Wang","year":"2016","unstructured":"Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus child-pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725\u201334.","journal-title":"Br J Surg"},{"key":"2481_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.21037\/atm.2020.02.85","volume":"8","author":"S Zhao","year":"2020","unstructured":"Zhao S, Wang M, Yang Z, et al. Comparison between child-pugh score and albumin-bilirubin grade in the prognosis of patients with hcc after liver resection using time-dependent Roc. Annals Translational Med. 2020;8:539.","journal-title":"Annals Translational Med"},{"key":"2481_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13014-019-1251-y","volume":"14","author":"T-S Su","year":"2019","unstructured":"Su T-S, Yang H-M, Zhou Y, et al. Albumin - bilirubin (albi) versus child-turcotte-pugh (ctp) in prognosis of hcc after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50.","journal-title":"Radiat Oncol"},{"key":"2481_CR28","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda H, Johnson PJ. The albi score: from liver function in patients with hcc to a general measure of liver function. JHEP Reports: Innov Hepatol. 2022;4:100557.","journal-title":"JHEP Reports: Innov Hepatol"},{"key":"2481_CR29","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/hepr.13673","volume":"51","author":"S Kaneko","year":"2021","unstructured":"Kaneko S, Kurosaki M, Tsuchiya K, et al. Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatol Research: Official J Japan Soc Hepatol. 2021;51:902\u20138.","journal-title":"Hepatol Research: Official J Japan Soc Hepatol"},{"key":"2481_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jso.25486","volume":"120","author":"DI Tsilimigras","year":"2019","unstructured":"Tsilimigras DI, Hyer JM, Moris D, et al. Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 706 patients. J Surg Oncol. 2019;120:206\u201313.","journal-title":"J Surg Oncol"},{"key":"2481_CR31","doi-asserted-by":"publisher","first-page":"8902146","DOI":"10.1155\/2018\/8902146","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Pang Q, Jin H, et al. Albumin-bilirubin grade as a novel predictor of survival in advanced extrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2018;2018:8902146.","journal-title":"Gastroenterol Res Pract"},{"key":"2481_CR32","doi-asserted-by":"publisher","first-page":"868034","DOI":"10.3389\/fonc.2022.868034","volume":"12","author":"N Wang","year":"2022","unstructured":"Wang N, Huang A, Kuang B, et al. Progress in radiotherapy for cholangiocarcinoma. Front Oncol. 2022;12:868034.","journal-title":"Front Oncol"},{"key":"2481_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Reviews Clin Oncol. 2018;15:95\u2013111.","journal-title":"Nat Reviews Clin Oncol"},{"key":"2481_CR34","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.12998\/wjcc.v7.i11.1242","volume":"7","author":"T Koo","year":"2019","unstructured":"Koo T, Park HJ, Kim K. Radiation therapy for extrahepatic bile duct cancer: current evidences and future perspectives. World J Clin Cases. 2019;7:1242\u201352.","journal-title":"World J Clin Cases"},{"key":"2481_CR35","unstructured":"Network NCC. Biliary tract cancers. Version: 3.2023. In: Editor, editor^editors. Book Biliary tract cancers. Version: 3.2023.; 2023."},{"key":"2481_CR36","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London England). 2014;383:2168\u201379.","journal-title":"Lancet (London England)"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02481-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:39:22Z","timestamp":1722497962000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2481"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02481-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3997276\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the University of Pennsylvania.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}